UK To Test Third Vaccine Dose In Immunocompromised People

Data From OCTAVE Study Show Low Response In 40% Of Patients After Two Doses

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".